



# Clinical differences in sarcoidosis patients with and without lymphoma: a single-centre retrospective cohort analysis

*To the Editor:*

Sarcoidosis is a systemic disease of unknown origin, characterised by the presence of noncaseating granulomas at disease sites [1]. A relevant clinical problem in the management of this disease is the coexistence of other clinical conditions, such as solid tumours or lymphomas, that may occur before or following the diagnosis of sarcoidosis, as well as simultaneously [2]. Particularly, the association of sarcoidosis and lymphoma is well established and was named the “sarcoidosis–lymphoma syndrome” by BRINCKER [3] and colleagues in 1986. In this syndrome, lymphoma occurs mainly in patients with a chronic active form of sarcoidosis, suggesting that chronic disease could be a risk factor for lymphoma. However, the distinctive clinical features of patients with sarcoidosis and lymphoma, and the precise mechanism underlying this association remain unclear.

We retrospectively reviewed the database of the Center for Rare Lung Diseases at the University Hospital of Modena (Modena, Italy) to identify all subjects with a diagnosis of sarcoidosis between 1990 and 2013, with the aim to evaluate clinical, functional and serological differences related to the presence of lymphoma in sarcoidosis patients, as well as differences in survival.

We recorded the following clinical data: sex, age, radiographic (*i.e.* Scadding) disease staging, organ involvement and treatment of both conditions, stage of lymphoma, sarcoidosis and lymphoma relapses, pulmonary function tests (PFTs), serology and haematology data, as well as serum angiotensin-converting enzyme (ACE) levels at the time of diagnosis. These parameters were compared between patients with and without lymphoma (table 1).

We retrieved 209 sarcoidosis patients and found 10 (4.8%) cases with a previous or subsequent diagnosis of lymphoproliferative disorder and a mean follow-up of 6.7 years and 9.5 years, respectively.

Differences between groups were tested with a two-sample t-test in continuous variables normally distributed with equal variances. The Chi-squared test was used to compare the distribution of categorical variables between the two groups, and the Fisher exact test when appropriate. Survival was estimated using the Kaplan–Meier method and compared between groups with the log-rank test.

There was no difference in patients' median age between the sarcoidosis and the sarcoidosis–lymphoma syndrome group (48.7 *versus* 46 years,  $p=0.578$ ). The majority of subjects within the sarcoidosis group were female; in contrast, a slight nonsignificant male predominance was observed in the sarcoidosis–lymphoma syndrome group ( $p=0.344$ ).

Most of the patients in the two groups were nonsmokers (60.7% and 85.7% in the sarcoidosis and sarcoidosis–lymphoma groups, respectively). A difference was found in terms of chest radiography staging, specifically a milder disease extent/severity in patients with lymphoma. In fact, stage II was the most common stage in the sarcoidosis group, while stage I was more frequently observed in the sarcoidosis–lymphoma group. PFTs trended towards worsening in the sarcoidosis group, wherein functional abnormalities were more likely to be present, although this difference did not reach statistical significance.

 @ERSpublications

**Patients with sarcoidosis showed a more frequent lung involvement and a restrictive ventilatory defect. Serum ACE was markedly higher in patients with sarcoidosis–lymphoma syndrome, indicating that those patients should be monitored over longer periods.** <http://bit.ly/327WBUM>

**Cite this article as:** Cerri S, Fontana M, Balduzzi S, *et al.* Clinical differences in sarcoidosis patients with and without lymphoma: a single-centre retrospective cohort analysis. *Eur Respir J* 2019; 54: 1802470 [<https://doi.org/10.1183/13993003.02470-2018>].

TABLE 1 Demographic and clinical characteristics of the study population

	Sarcoidosis	Sarcoidosis-lymphoma	p-value
<b>Patients n</b>	199	10	
<b>Age years</b>	48.7±14.8	46±12	0.578
<b>Sex</b>			
Male	89 (44.7)	6 (60.0)	0.344
Female	110 (55.3)	4 (40.0)	
<b>Smoking history</b>			
Nonsmokers	105 (60.7)	6 (85.7)	0.630
Ex-smokers	26 (15)	0 (0)	
Current smokers	42 (24.3)	1 (14.3)	
<b>FVC L</b>	3.3±1.1	4.2±0.8	0.052
<b>FVC % pred</b>	96.2±18.0	100.1±19.2	0.583
<b>FEV<sub>1</sub> L</b>	2.7±0.9	3.3±0.6	0.92
<b>FEV<sub>1</sub> % pred</b>	94.4±19.1	97.1±18.0	0.720
<b>D<sub>LCO</sub> mL·min<sup>-1</sup>·kPa<sup>-1</sup></b>	6.2±2.6	7.4±1.8	0.234
<b>D<sub>LCO</sub> % pred</b>	73.9±23.8	75.3±15.3	0.881
<b>Chest radiography stages</b>			
Stage 0	15 (7.5)	0 (0)	
Stage I	59 (29.7)	5 (50.0)	
Stage II	89 (44.7)	3 (30.0)	0.671
Stage III	30 (15.1)	2 (20.0)	
Stage IV	6 (3.0)	0 (0)	
<b>ACE U·L<sup>-1</sup></b>			
At diagnosis	55.8±36.7	94.9±43.9	0.02
First relapse	86.0±56.4		N/A
Last follow-up	50.7±41.7	83.3±42.5	0.047
<b>Relapses</b>	36 (18.9)	0 (0)	N/A
<b>Organ involvement</b>			
Mediastinum	159 (79.9)	8 (80.0)	0.994
Lungs	137 (68.8)	7 (70.0)	0.939
Skin	53 (26.6)	4 (40.0)	0.354
Lymph nodes	34 (17.6)	3 (30.0)	0.321
Eyes	12 (6.0)	1 (10.0)	0.612
Spleen	12 (6.0)	1 (10.0)	0.612
Liver	17 (8.5)	0 (0)	0.335
Salivary glands	5 (2.5)	0 (0)	0.999
Nervous system	7 (3.5)	0 (0)	0.999
Hypercalcaemia	1 (0.5)	0 (0)	0.999
Bones	2 (1.0)	1 (10.0)	0.137
ENT	1 (0.5)	0 (0)	0.999
Gastrointestinal	2 (1.0)	0 (0)	0.999
Lacrimal glands	1 (0.5)	1 (10.0)	0.094
Bone marrow	2 (1.0)	0 (0)	0.999
Heart	1 (0.5)	0 (0)	0.999
Testis	1 (0.5)	0 (0)	0.999

Data are presented as mean±SD or n (%), unless otherwise stated. FVC: forced vital capacity; FEV<sub>1</sub>: forced expiratory volume in 1 s; D<sub>LCO</sub>: diffusing capacity of the lung for carbon monoxide; ACE: angiotensin-converting enzyme; ENT: ear, nose and throat; N/A: not applicable.

(forced vital capacity 3.3 versus 4.2 L in sarcoidosis and sarcoidosis-lymphoma, respectively; p=0.052). In addition, 36 (18.9%) relapses of sarcoidosis were reported in the sarcoidosis group, while no relapse was observed in the sarcoidosis-lymphoma group.

We detected a statistically significant difference in ACE serum levels between groups. Indeed, in the sarcoidosis-lymphoma syndrome group, serum ACE level was significantly higher compared to patients without lymphoma, both at the time of the diagnosis of sarcoidosis (94.9 U·L<sup>-1</sup> versus 55.8 U·L<sup>-1</sup>, respectively; p=0.02) and at the last measurement available (83.3 U·L<sup>-1</sup> versus 50.7 U·L<sup>-1</sup>, respectively; p=0.047).

Survival did not differ between the two groups (log-rank test p=0.3724).



In the present study, we investigated whether serological, clinical, functional or radiological features may help differentiate patients with sarcoidosis from those with sarcoidosis–lymphoma syndrome. We showed that lung involvement as assessed by chest radiograph (Scadding radiographic stage II), a restrictive ventilatory defect and a higher rate of relapse were more common among patients with sarcoidosis alone. Furthermore, and perhaps more interestingly, serum ACE levels were higher in patients with sarcoidosis–lymphoma syndrome both at the time of the diagnosis and at the last follow-up measurement available, indicating that patients with persistently elevated serum ACE levels should probably be monitored carefully over longer periods, despite the similar outcomes in term of mortality observed in the two groups.

Previous epidemiological studies showed an increased incidence of various types of cancers in patients with sarcoidosis [4], but this association does not seem to be cancer-specific. However, breast and testicular tumours are more frequently described in association with sarcoidosis [5], and may occur either before, concurrent with, or after onset of sarcoidosis [2, 6]. In patients with either haematological malignancies or solid tumours, granulomatous inflammation is a frequent finding, mainly in the local lymph nodes draining the cancer site [7]. However, these “sarcoid-like” reactions have limited clinical relevance and should not be regarded as sarcoidosis.

Coexistence of sarcoidosis and lymphoma is well known. Indeed, patients with sarcoidosis are up to 11 times more likely to develop lymphoma as compared to the general population [8]. Specifically, an increased risk of Hodgkin lymphoma was observed in patients with sarcoidosis in a population-based case–control study in Scandinavia [4]. In the majority of cases, lymphoma occurred after sarcoidosis, usually within a short time interval [9]. Patients with sarcoidosis–lymphoma syndrome tend to be significantly older than unselected individuals with sarcoidosis [10]. In contrast, in our study, no differences were observed in the median age of patients with or without lymphoma. Different genetic backgrounds or environmental exposures may account for this inconsistent finding [1]. Similar to our study, BLANK *et al.* [11] performed a retrospective study analysing the incidence and type of malignancies in a large cohort of patients with sarcoidosis, showing a similar rate of lymphoproliferative disorders (4.1% versus 4.8% in our study), thus confirming the generalisability of our findings.

In our study, a number of limitations should be acknowledged, the main being the small number of patients with sarcoidosis–lymphoma syndrome, although, reassuringly, a comparable prevalence of sarcoidosis–lymphoma syndrome was found in previous similar studies [11]. Moreover, the retrospective design is prone to incomplete or missing data. Finally, the lack of a control population without sarcoidosis followed over the same period of time precludes us from identifying sarcoidosis as a risk factor for malignancy. These limitations notwithstanding, our data suggest that in patients with sarcoidosis persistently elevated serum ACE levels should raise the suspicion of supervening lymphoma. ACE is generally used to monitor disease behaviour during follow-up [1]. Thus, we argue that serum ACE levels may reflect the intensity of the lymphocytic activation occurring in patients with sarcoidosis, and that an exuberant and uncontrolled lymphocytic activation, perhaps not counterbalanced by T-regulatory cell activity [12], may trigger the development of lymphoma. In support of our hypothesis, evidence suggests that serum ACE is lower in patients with lymphoma alone [13]. Interestingly, we also observed that the CD4/CD8 lymphocyte ratio in bronchoalveolar lavage was higher among patients with sarcoidosis–lymphoma syndrome (data not shown), further supporting the hypothesis of an aberrant lymphocytic activation (T-helper) in patients with both conditions.

In conclusion, our study suggests the existence of clinical, radiological and serological differences in sarcoidosis with or without lymphoma syndrome. Larger prospective studies are required to confirm and expand on these observations.

**Stefania Cerri<sup>1</sup>, Matteo Fontana<sup>1</sup>, Sara Balduzzi<sup>2</sup>, Leonardo Potenza<sup>3</sup>, Paola Faverio<sup>4</sup>, Mario Luppi<sup>3</sup>, Roberto D’Amico<sup>2</sup>, Paolo Spagnolo<sup>5</sup>, Enrico Clini <sup>1</sup> and Fabrizio Luppi <sup>4</sup>**

<sup>1</sup>Dept of Medical and Surgical Sciences, Center for Rare Lung Diseases, Respiratory Disease Unit, University Hospital of Modena, Modena, Italy. <sup>2</sup>Dept of Medical and Surgical Sciences, Statistics Unit, University Hospital of Modena and Reggio Emilia, Modena, Italy. <sup>3</sup>Dept of Medical and Surgical Sciences, Hematology Unit, University of Modena and Reggio Emilia, Modena, Italy. <sup>4</sup>Cardio-Thoracic-Vascular Dept, Respiratory Unit, University of Milan Bicocca, San Gerardo Hospital, ASST Monza, Monza, Italy. <sup>5</sup>Dept of Cardiac, Thoracic and Vascular Sciences, Section of Respiratory Diseases, University of Padova, Padova, Italy.

Correspondence: Fabrizio Luppi, Cardio-Thoracic-Vascular Dept, University of Milan Bicocca, Respiratory Unit, San Gerardo Hospital, ASST Monza, Monza, Italy. E-mail: fabrizio.luppi@unimib.it

Received: 08 Jan 2019 | Accepted after revision: 09 July 2019

Conflict of interest: S. Cerri has nothing to disclose. M. Fontana has nothing to disclose. S. Balduzzi has nothing to disclose. L. Potenza has nothing to disclose. P. Faverio has nothing to disclose. M. Luppi has nothing to disclose. R. D’Amico has nothing to disclose. P. Spagnolo reports personal fees and non-financial support from Roche,

Boehringer Ingelheim, Zambon and PPM Services, and personal fees from Galapagos, outside the submitted work. E. Clini has nothing to disclose. F. Luppi has nothing to disclose.

Support statement: We acknowledge that this research was partially supported by the Italian Ministry of University and Research (MIUR) – Department of Excellence project PREMIA (PRECision Medicine Approach: bringing biomarker research to clinic).

## References

- 1 Statement on sarcoidosis. Joint Statement of the American Thoracic Society (ATS), the European Respiratory Society (ERS) and the World Association of Sarcoidosis and Other Granulomatous Disorders (WASOG) adopted by the ATS Board of Directors and by the ERS Executive Committee, February 1999. *Am J Respir Crit Care Med* 1999; 160: 736–755.
- 2 Spagnolo P, Luppi F, Roversi P, *et al.* Sarcoidosis: challenging diagnostic aspects of an old disease. *Am J Med* 2012; 125: 118–125.
- 3 Brincker H. The sarcoidosis-lymphoma syndrome. *Br J Cancer* 1986; 54: 467–473.
- 4 Askling J, Grunewald J, Eklund A, *et al.* Increased risk for cancer following sarcoidosis. *Am J Respir Crit Care Med* 1999; 160: 1668–1672.
- 5 Rayson D, Burch PA, Richardson RL. Sarcoidosis and testicular carcinoma. *Cancer* 1998; 83: 337–343.
- 6 Grados A, Ebbo M, Bernit E, *et al.* Sarcoidosis occurring after solid cancer: a nonfortuitous association: report of 12 cases and review of the literature. *Medicine* 2015; 94: e928.
- 7 Brincker H. Sarcoid reactions in malignant tumours. *Cancer Treat Rev* 1986; 13: 147–156.
- 8 Brincker H, Wilbeck E. The incidence of malignant tumours in patients with respiratory sarcoidosis. *Br J Cancer* 1974; 29: 247–251.
- 9 London J, Grados A, Fermé C, *et al.* Sarcoidosis occurring after lymphoma: report of 14 patients and review of the literature. *Medicine* 2014; 93: e121.
- 10 Rybicki BA, Major M, Popovich J Jr, *et al.* Racial differences in sarcoidosis incidence: a 5-year study in a health maintenance organization. *Am J Epidemiol* 1997; 145: 234–241.
- 11 Blank N, Lorenz HM, Ho AD, *et al.* Sarcoidosis and the occurrence of malignant diseases. *Rheumatol Int* 2014; 34: 1433–1439.
- 12 Broos CE, van Nimwegen M, Hoogsteden HC, *et al.* Granuloma formation in pulmonary sarcoidosis. *Front Immunol* 2013; 4: 437.
- 13 Romer FK, Emmertsen K. Serum angiotensin-converting enzyme in malignant lymphomas, leukaemia and multiple myeloma. *Br J Cancer* 1980; 42: 314–318.

Copyright ©ERS 2019